Adare Pharmaceuticals

Adare Pharmaceuticals

A pharmaceutical company focused on making products to improve the microbiome.

All edits by  Dawson Sewell 

Edits on 7 Jul, 2019
Dawson Sewell
Dawson Sewell edited on 7 Jul, 2019
Edits made to:
Description (+79/-7 characters)
Topic thumbnail

Adare Pharmaceuticals

Company

A pharmaceutical company focused on making products to improve the microbiome.

Edits on 11 Apr, 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 11 Apr, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Industry
Biotechnology
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 11 Apr, 2019
Edits made to:
Infobox (+1 properties)
Infobox
Industry
Microbiome
Edits on 20 Mar, 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 20 Mar, 2019
Edits made to:
Article (+25/-25 characters)
Article

Lacteol is a proprietary combination of Lactobacillus fermentum and Lactobacillus delbrueckiiLactobacillus delbrueckii and fermented culture medium. In addition to rehydration and dietary measures the product is used as a supplemental treatment for diarrhea in adults and children. The company develops products in therapeutic categories of cardiovascular, pain management, GI and CNS as well as taste management an oral disintegration of tablets.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 20 Mar, 2019
Edits made to:
Article (+10/-10 characters)
Article

Adare Pharmaceuticals was formerly called Aptalis Pharmatech until 2015 when it was aquired by global investment firm, TPG. Adare Pharmaceuticals utilizes its Pharmaceutical Technology and MicrobiomeMicrobiome scientific platforms to develop novel products. Adare provides co-development and contract services to biopharmaceutical companies to develop and manufacture products that are marketed by its partners. Through its Adare Development affiliate, Adare invests in its own product pipeline. Products developed and manufactured by Adare include LacteolTM, ZoolacTM, ViactivTM, Amrix ® as well as branded and complex generic products.

Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 19 Mar, 2019
Edits made to:
Article (+24/-24 characters)
Article

In March 2019, Adare Pharmaceuticals (Adare) announced positive results from its Phase IIb study (FLUTETM) for one of its rare disease investigational products, APT-1011 (AdvaTab® Fluticasone) for Eosinophilic EsophagitisEosinophilic Esophagitis (EoE). Eosinophilic Esophagitis (EoE) is a chronic, allergic inflammatory disease. The disease is characterized by eosinophilic infiltration of the esophagus which can put patients at risk for food imaction due to inflammation and development of strictures and narrowing of the esophagus. APT-1011 is a novel formulation incorporating Adare's proprietary AdvaTab® technology is a fluticasone product. Fluticasone is a corticosteroid treatment that reduces swelling or inflammation in the nasal passages. APT-1011 is an oral formulation of fluticasone that allows topical delivery to the esophagus and minimizes time in the oral cavity. At the time of this announcement there were no FDA approved EoE treatments available in the US.EoE treatments include food elimination diets, off-label use of proton pump inhibitors and glucocorticoid steroid formulations.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.